CLINICAL AND BIOMARKER REMISSION IS MAINTAINED AFTER SWITCH FROM MONTHLY DOSED VEDOLIZUMAB TO THE NOVEL SUBCUTANEOUS FORMULATION IN INFLAMMATORY BOWEL DISEASE

Špela Pintar  1     Jurij Hanzel  1     Natasa Smrekar  1     Matic Koželj  1     David Drobne  1     Tina Kurent Francky  1     Borut Stabuc  1     Gregor Novak  1    
1 University Medical Centre Ljubljana, Ljubljana, Slovenia

Session
Investigator studies in IBD I (Posters)

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)

Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing